Institute of Cancer Research

Plenty of biopharmaceutical firms continue to struggle to raise fresh capital under current financial market conditions with drug developer valuations still well below what they were a few years ago a

The pace of cancer partnering between the biopharma industry and academic and institutional research entities during the final months of 2022 remained typically brisk, and two US institutions – The U

It appears that venture capital investment in biopharmaceutical companies still has not been impacted yet by the COVID-19 pandemic, given the number of large financings announced in recent weeks, but

Dublin-based Carrick Therapeutics Ltd. has licensed exclusive worldwide rights to develop and commercialize BTG945, now known as CT900, an investigational targeted ovarian cancer drug, from BTG PLC